WuXi XDC Cayman (FRA:L74) Change In Working Capital : €-9.6 Mil (TTM As of Jun. 2023)

View and export this data going back to 2023. Start your Free Trial

What is WuXi XDC Cayman Change In Working Capital?

WuXi XDC Cayman's change in working capital for the quarter that ended in Jun. 2023 was €8.2 Mil.

WuXi XDC Cayman's change in working capital for the fiscal year that ended in Dec. 2023 was €-12.1 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

WuXi XDC Cayman Change In Working Capital Historical Data

The historical data trend for WuXi XDC Cayman's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi XDC Cayman Change In Working Capital Chart

WuXi XDC Cayman Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

-2.75

-8.18

-0.81

-12.13

WuXi XDC Cayman Quarterly Data
	Dec20	Dec21	Mar22	Jun22	Dec22	Mar23	Jun23	Dec23
Change In Working Capital	Get a 7-Day Free Trial			-11.73	-	-17.78	8.17	-

WuXi XDC Cayman Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-9.6 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

WuXi XDC Cayman Change In Working Capital Related Terms

Thank you for viewing the detailed overview of WuXi XDC Cayman's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

WuXi XDC Cayman (FRA:L74) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » WuXi XDC Cayman Inc (FRA:L74) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

02268:Hong Kong

Address

No. 11 Xinhui Ring Road, Xinwu, Jiangsu, Wuxi, CHN

Website

WuXi XDC Cayman Inc is a leading CRDMO focused on the global ADC and broader bioconjugate market and the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, It offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development and manufacturing. The company provides these services from proximately located, state-of-the-art laboratories and manufacturing facilities, leading to the significant reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development and manufacturing platform, its mission is to continuously enhance its platform, and propel and transform the development of the bioconjugate industry.

WuXi XDC Cayman (FRA:L74) Headlines

No Headlines